NICE says yes to Alcon's Jetrea
This article was originally published in Scrip
Alcon/ThromboGenic's Jetrea (ocriplasmin) is soon to be the first drug routinely available on England's National Health Service for treating vitreomacular traction and macular hole. NICE, the health technology appraisal institute, for England and Wales has issued final draft guidance recommending the product.
You may also be interested in...
While information sharing is key to cross-country collaborations on access to medicines and can lead to major benefits, it is hard to sell to political leaders and the media, says a report from the World Health Organization’s regional office for Europe.
The European Commission says it will publish its review of the EU orphan drug legislation in the coming days.
The UK has formally withdrawn its ratification of the Unified Patent Court Agreement, adding to the uncertainty over its future.